IRIS UniCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.215
AS - Asia 4.105
EU - Europa 3.626
SA - Sud America 775
AF - Africa 114
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.847
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.038
SG - Singapore 1.978
CN - Cina 839
DE - Germania 820
IT - Italia 700
BR - Brasile 635
SE - Svezia 443
NL - Olanda 408
VN - Vietnam 368
FR - Francia 340
IE - Irlanda 221
GB - Regno Unito 172
IN - India 152
JP - Giappone 147
ID - Indonesia 110
HK - Hong Kong 95
RU - Federazione Russa 92
FI - Finlandia 90
CA - Canada 79
KR - Corea 67
BD - Bangladesh 59
TR - Turchia 58
PL - Polonia 56
AR - Argentina 55
MX - Messico 55
ES - Italia 49
IQ - Iraq 48
UA - Ucraina 34
ZA - Sudafrica 30
AT - Austria 25
CZ - Repubblica Ceca 25
IL - Israele 24
BE - Belgio 23
PK - Pakistan 22
CH - Svizzera 17
CO - Colombia 17
EC - Ecuador 17
IR - Iran 17
PA - Panama 17
VE - Venezuela 17
RO - Romania 15
SA - Arabia Saudita 15
LT - Lituania 14
MA - Marocco 14
EG - Egitto 13
MK - Macedonia 13
JO - Giordania 12
PH - Filippine 12
PT - Portogallo 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
CI - Costa d'Avorio 11
RS - Serbia 11
UZ - Uzbekistan 11
KE - Kenya 9
PY - Paraguay 8
UY - Uruguay 8
NP - Nepal 7
OM - Oman 7
PE - Perù 7
AL - Albania 6
BG - Bulgaria 6
KZ - Kazakistan 6
MY - Malesia 6
AU - Australia 5
CL - Cile 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
HR - Croazia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
AZ - Azerbaigian 4
BO - Bolivia 4
GR - Grecia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
BH - Bahrain 3
CR - Costa Rica 3
DZ - Algeria 3
LK - Sri Lanka 3
LY - Libia 3
NG - Nigeria 3
NI - Nicaragua 3
BT - Bhutan 2
BY - Bielorussia 2
DM - Dominica 2
EE - Estonia 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
ME - Montenegro 2
PR - Porto Rico 2
SI - Slovenia 2
SV - El Salvador 2
TW - Taiwan 2
Totale 12.819
Salva come PNG Salva come JPEG
Città #
Singapore 1.171
Ashburn 591
San Jose 485
Chandler 460
Amsterdam 367
Frankfurt am Main 277
New York 218
Dublin 202
Hefei 184
Rome 184
Los Angeles 161
Beijing 139
Tokyo 139
Ho Chi Minh City 120
Milan 112
Jakarta 102
Lauterbourg 100
Hanoi 93
Hong Kong 84
São Paulo 68
Chicago 66
Seoul 66
Boston 65
Munich 64
Dallas 59
Kent 53
Helsinki 51
Marseille 47
The Dalles 47
Moscow 43
Santa Clara 42
Buffalo 40
Pune 38
San Mateo 38
Warsaw 37
Orem 36
Princeton 36
London 34
Nuremberg 33
Paris 33
Denver 32
Council Bluffs 31
Atlanta 29
Montreal 29
Houston 27
Chennai 24
Toronto 24
Poplar 23
Rio de Janeiro 22
Stockholm 22
Ann Arbor 21
Baghdad 21
Johannesburg 21
Shanghai 21
Brooklyn 20
Dearborn 20
Mexico City 20
Palermo 20
Wilmington 20
Brussels 19
Da Nang 18
Düsseldorf 18
Nanjing 18
Belo Horizonte 17
Bremen 17
San Francisco 17
Seattle 17
Ankara 16
Brno 16
Haiphong 16
Turku 16
Hyderabad 15
Lappeenranta 15
Falkenstein 14
Boardman 13
Brasília 13
Columbus 13
Jacksonville 13
Amman 12
Augusta 12
Bexley 12
Phoenix 12
Portsmouth 12
Turin 12
Vienna 12
Abidjan 11
Biên Hòa 11
Cattolica 11
Charlotte 11
Redwood City 11
St Louis 11
Andover 10
City of London 10
Curitiba 10
Dhaka 10
Edinburgh 10
Manchester 10
New Delhi 10
Salvador 10
Skopje 10
Totale 7.173
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 946
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 266
Assessing floppy infants: a new module 201
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 189
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 187
Developmental milestones in type I spinal muscular atrophy 186
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 175
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 170
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 163
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 163
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 160
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 159
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 158
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 155
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 154
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 153
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 149
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 149
Predominant distal muscle involvement in spinal muscular atrophy 147
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 145
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 143
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 141
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 141
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 136
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 134
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 133
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 131
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 131
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 131
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 130
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 130
Early treatment of type II SMA slows rate of progression of scoliosis 129
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 129
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 128
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 128
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 126
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 124
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 122
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 121
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 121
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 120
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 119
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 119
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 118
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 117
New therapies for spinal muscular atrophy: where we stand and what is next 116
Developmental milestones in type I spinal muscular atrophy 114
Clinical Variability in Spinal Muscular Atrophy Type III. 112
Sleep disorders in spinal muscular atrophy 111
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 111
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 111
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 110
Revised upper limb module for spinal muscular atrophy: Development of a new module 109
An observational study of functional abilities in infants, children, and adults with type 1 SMA 106
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 106
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 102
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 102
Development of an academic disease registry for spinal muscular atrophy 102
Risdiplam in Type 1 Spinal Muscular Atrophy 101
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 96
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 95
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 94
An observational study of functional abilities in infants, children, and adults with type 1 SMA 93
Gain and loss of abilities in type II SMA: A 12-month natural history study 92
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 91
Long term follow-up of scoliosis progression in type II SMA patients 90
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 90
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 90
Longitudinal natural history of type I spinal muscular atrophy: A critical review 90
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 90
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 87
Old measures and new scores in spinal muscular atrophy patients 86
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 86
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 85
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 84
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 84
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 83
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 82
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 82
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 82
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 81
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 81
null 81
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 79
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 79
Neonatal hypotonia and neuromuscular conditions 78
Spinal muscular atrophy — insights and challenges in the treatment era 78
Revised upper limb module for spinal muscular atrophy: 12 month changes 77
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 76
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 75
Risdiplam in Type 1 Spinal Muscular Atrophy 72
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 70
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 70
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 69
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 68
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 68
Early neurodevelopmental assessment in Duchenne muscular dystrophy 66
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 64
Totale 12.343
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 5 18 2
2021/2022449 30 6 5 63 34 13 9 63 33 27 70 96
2022/20231.646 108 175 109 222 109 201 104 169 253 42 90 64
2023/20241.332 44 268 51 136 51 243 142 59 18 68 110 142
2024/20252.411 49 43 158 115 194 125 102 96 338 203 540 448
2025/20266.852 806 209 429 885 1.210 1.220 1.061 290 364 378 0 0
Totale 13.003